SAN DIEGO--(BUSINESS WIRE)--July 17, 2006--Cytori Therapeutics, Inc. (NASDAQ:CYTX - News; Frankfurt:XMPA - News), today reported top-line preliminary results demonstrating that adipose-derived stem and regenerative cells from its proprietary Celution(TM) System was safe and improved heart function in a chronic ischemia model, representing a severe form of coronary artery disease. The study was conducted by Emerson Perin, M.D., Ph.D., at The Texas Heart Institute in collaboration with Cytori. The full data and analysis of this study will be presented later this year.
